Artal Group S.A. - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 208 filers reported holding BRIDGEBIO PHARMA INC in Q2 2021. The put-call ratio across all filers is 1.95 and the average weighting 0.6%.

Quarter-by-quarter ownership
Artal Group S.A. ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q1 2023$8,290
+335.2%
500,000
+100.0%
0.49%
+365.1%
Q4 2022$1,905
-99.9%
250,0000.0%0.11%0.0%
Q3 2022$2,485,000
+9.5%
250,0000.0%0.11%
-12.4%
Q2 2022$2,270,000
-10.6%
250,0000.0%0.12%
+14.2%
Q1 2022$2,538,000
-39.1%
250,0000.0%0.11%
-6.2%
Q4 2021$4,170,000
-64.4%
250,0000.0%0.11%
-56.9%
Q3 2021$11,718,000
-30.1%
250,000
-9.1%
0.26%
-22.9%
Q2 2021$16,764,000
+8.9%
275,000
+10.0%
0.34%
+25.0%
Q1 2021$15,400,000
-27.8%
250,000
-16.7%
0.27%
-40.6%
Q4 2020$21,333,000
+42.1%
300,000
-25.0%
0.46%
+25.8%
Q3 2020$15,008,000
-23.3%
400,000
-33.3%
0.36%
-33.5%
Q2 2020$19,566,000
+22.7%
600,000
+9.1%
0.55%
-18.8%
Q1 2020$15,950,000
+127.5%
550,000
+175.0%
0.67%
+148.7%
Q4 2019$7,010,000
+63.3%
200,0000.0%0.27%
+57.6%
Q3 2019$4,294,000
-20.4%
200,0000.0%0.17%
-21.1%
Q2 2019$5,394,000200,0000.22%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q2 2021
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$160,016,45665.94%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$819,077,80528.79%
Cormorant Asset Management, LP 4,662,530$122,950,9167.17%
Frazier Life Sciences Management, L.P. 2,725,949$71,883,2754.77%
Octagon Capital Advisors LP 971,639$25,622,1203.94%
M28 Capital Management LP 121,200$3,196,0443.66%
VIKING GLOBAL INVESTORS LP 25,120,991$662,440,5332.69%
BOONE CAPITAL MANAGEMENT LLC 313,381$8,263,8572.61%
Fernwood Investment Management, LLC 235,620$6,213,2992.23%
SOUTHPORT MANAGEMENT, L.L.C. 15,000$395,5502.15%
View complete list of BRIDGEBIO PHARMA INC shareholders